L‐type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel‐resistant prostate cancer by inhibiting cyclin‐dependent kinase activity
Cancer Science · 2024
DOI: 10.1111/cas.16062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Junryo Rii und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. Hauptthemen laut MEDLINE: Large Neutral Amino Acid-Transporter 1, Prostatic Neoplasms, Benzoxazoles, Taxoids. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Grants-in-Aid for Scientific Research of the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Abstract (Originalsprache)
L‐type amino acid transporter 1 (LAT1, SLC7A5 ) is an amino acid transporter expressed in various carcinomas, and it is postulated to play an important role in the proliferation of cancer cells through the uptake of essential amino acids. Cabazitaxel is a widely used anticancer drug for treating castration‐resistant prostate cancer (CRPC); however, its effectiveness is lost when cancer cells acquire drug resistance. In this study, we investigated the expression of LAT1 and the effects of a LAT1‐specific inhibitor, JPH203, in cabazitaxel‐resistant prostate cancer cells. LAT1 was more highly expressed in the cabazitaxel‐resistant strains than in the normal strains. Administration of JPH203 inhibited the growth, migration, and invasive ability of cabazitaxel‐resistant strains in vitro. Phosphoproteomics using liquid chromatography‐mass spectrometry to comprehensively investigate changes in phosphorylation due to JPH203 administration revealed that cell cycle‐related pathways were affected by JPH203, and that JPH203 significantly reduced the kinase activity of cyclin‐dependent kinases 1 and 2. Moreover, JPH203 inhibited the proliferation of cabazitaxel‐resistant cells in vivo. Taken together, the present study results suggest that LAT1 might be a valuable therapeutic target in cabazitaxel‐resistant prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
- Bio-System Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan.
- Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan.
ORCID-Profile: Junryo Rii, Shinichi Sakamoto, Yasutaka Yamada, Yoshikatsu Kanai
Förderung
- Grants-in-Aid for Scientific Research of the Ministry of Education, Culture, Sports, Science and Technology of Japan
Zitieren
APA
Rii, J., Sakamoto, S., Mizokami, A., Xu, M., Fujimoto, A., Saito, S., Koike, H., Tamura, T., Arai, T., Yamada, Y., Goto, Y., Sazuka, T., Imamura, Y., Suzuki, K., Kanai, Y., Anzai, N., & Ichikawa, T. (2024). L‐type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel‐resistant prostate cancer by inhibiting cyclin‐dependent kinase activity. Cancer Science. https://doi.org/10.1111/cas.16062
Vancouver
Rii J, Sakamoto S, Mizokami A, Xu M, Fujimoto A, Saito S, et al. L‐type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel‐resistant prostate cancer by inhibiting cyclin‐dependent kinase activity. Cancer Science. 2024. doi:10.1111/cas.16062
BibTeX
@article{Rii2024,
author = {Rii, Junryo and Sakamoto, Shinichi and Mizokami, Atsushi and Xu, Minhui and Fujimoto, Ayumi and Saito, Shinpei and Koike, Hidekazu and Tamura, Takaaki and Arai, Takayuki and Yamada, Yasutaka and Goto, Yusuke and Sazuka, Tomokazu and Imamura, Yusuke and Suzuki, Kazuhiro and Kanai, Yoshikatsu and Anzai, Naohiko and Ichikawa, Tomohiko},
title = {L‐type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel‐resistant prostate cancer by inhibiting cyclin‐dependent kinase activity},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16062}
}
EUVIMED